Skip to content

ResMed RMD Finished goods

Finished goods at other companies

LivaNova logo
LivaNovaLIVN
$75.09M+12.2%
Pulmonx Corporation logo
Pulmonx CorporationLUNG
$14.76M+3.2%
Eli Lilly logo
Eli LillyLLY
Medtronic logo
MedtronicMDT
Baxter International logo
Baxter InternationalBAX

Other financials

Income statement

See full
Revenue$1.4B+10.8%
Gross profit$891.0M+16.3%
Operating income$499.8M+17.3%
Net income$398.7M+9.2%
EPS (diluted)$2.74+10.5%

Balance sheet

See full
Cash & equivalents$1.7B+78.0%
Total debt$1.1B+29.8%
Total equity$6.5B+17.1%
Total assets$8.8B+16.1%

Cash flow

See full
Operating cash flow$554.1M-4.2%
CapEx$33.7M+61.8%
Free cash flow$520.5M-6.7%

Valuation

See full
Market cap$28.27B-19.1%
Enterprise value$27.71B-19.8%
P/E18.6×-6.3×
P/S5.1×-1.7×

Profitability

See full
Gross margin61.6%+2.8pp
Operating margin34.2%+2.1pp
Net margin27.4%+1.3pp
FCF margin31.7%+0.4pp

Returns & leverage

See full
Return on equity25.2%-0.6pp
Debt / equity0.2×0.0×
Current ratio-0.4×

Where this comes from

Reported directly by ResMed in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoodsNetOfReserves.

The official record: ResMed’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about ResMed's finished goods.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ResMed's finished goods?
ResMed (RMD) reported finished goods of $558.97M in Q1 2026.
How has ResMed's finished goods changed year-over-year?
ResMed's finished goods increased by 8.2% year-over-year, from $516.38M to $558.97M.
What is the long-term trend for ResMed's finished goods?
Over 4 years (2021 to 2025), ResMed's finished goods has grown at a 17.1% compound annual growth rate (CAGR), from $296.97M to $557.88M.
What does finished goods mean?
Completed products ready for sale, valued at the lower of cost or net realizable value.